非那雄胺联合坦洛新治疗良性前列腺增生症伴慢性前列腺炎疗效观察  

Clinical Effects of Finasteride Combined Tamsulosin on Benign Prostatic Hyperplasia with Chronic Prostatitis

作　　者：陈大可[1] 黄卫文[1] 鲍文朔[1] 

机构地区：[1]浙江省温州市第三人民医院,温州325000

出　　处：《浙江中医药大学学报》2011年第2期191-192,共2页Journal of Zhejiang Chinese Medical University

摘　　要：[目的]观察非那雄胺联合坦洛新治疗BPH伴CP的临床疗效。[方法]选择BPH伴CP患者40例,口服非那雄胺(5mg/d)和坦洛新(0.2mg/d)3个月,在治疗前和治疗3个月后分别检查国际前列腺症状评分(IPSS)、尿流率、残余尿量、前列腺体积、前列腺液常规等指标。[结果]治疗后IPSS平均降低27.8%,最大尿流率平均升高37.0%,残余尿量平均减少39.4%,前列腺体积平均缩小18.4%,前列腺液中白细胞计数平均减少38.9%。前列腺液检查好转率60.0%,其中前列腺体积≥40ml组和<40ml组的前列腺液检查好转率分别为70.8%及43.7%,两组间比较差异有统计学意义(P<0.05)。[结论]非那雄胺联合坦洛新可有效治疗伴CP的BPH患者,对前列腺体积较大者效果更好。[Objective]To observe the clinical efficacy of finasteride combined Tamsulosin on benign prostatic hyperplasia(BPH) with chronic prostatitis(CP).[Methods] 40 patients with BPH and CP had received oral administ ration of finasteride(5mg/d) and Tamsulosin(0.2mg/d) for 3 months.IPSS,urine flow rate,residual urine volume,prostatic volumeand expressed prostatic secretion(EPS) were detected before and after treatment.[Results] After treatment,maximalurine flow rate increased by 37.0%,but IPSS,residual urine volume,prostatic volume and leucocyte count in EPS decreased by 27.8%,39.4%,18.4% and 38.9% on average respectively.Total improvement rate of EPS examination was 60.0%,but the improvement rate in patients with prostatic volume ≥40ml was superior to that in patients with prostatic volume < 40ml(70.8% vs 43.7%).[Conclusion] Combined use of inasteride and Tamsulosin is effective for treating patients with BPH and CP,especially for those with bigger prostate.

关 键 词：前列腺炎 前列腺增生 非那雄胺 坦洛新 

分 类 号：R2[医药卫生—中医学]